Payment overview · 2025
General Payments
$126.99
2 reported records · 2 companies
Healthcare provider profile · identity verified
Phillip David Roberts, DO
Allopathic & Osteopathic Physicians|Family Medicine · PORTSMOUTH, OH · NPI 1871742338
Verified facts
What the public records show
CMS Open Payments records show Phillip David Roberts, DO received $126.99 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 86.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $110.09 | 86.7% | 1 | 2025 |
| CashFlow Solutions, LLC | Unresolved — no canonical attribution shown | $16.90 | 13.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $126.99 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $110.09 | 1 | 2025 |
Source payment records
|
|||||
| LYMPHA PRESS OPTIMAL PLUS(US) BT Normalized: lympha press optimal plus us bt |
Device | CashFlow Solutions, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| PCD-51 731A (US) - White Normalized: pcd 51 731a us white |
Device | CashFlow Solutions, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| PCD-52 737A (US) White Normalized: pcd 52 737a us white |
Device | CashFlow Solutions, LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
102 | 29 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 555 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 422 | 95 |
| Losartan Potassium | Losartan Potassium | 333 | 91 |
| Metformin Hcl | Metformin Hcl | 279 | 68 |
| Gabapentin | Gabapentin | 274 | 58 |
| Lisinopril | Lisinopril | 246 | 69 |
| Amlodipine Besylate | Amlodipine Besylate | 240 | 66 |
| Ozempic | Semaglutide | 230 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 62 |
| Omeprazole | Omeprazole | 218 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 176 | 48 |
| Potassium Chloride | Potassium Chloride | 173 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 52 |
| Trulicity | Dulaglutide | 169 | 27 |
| Jardiance | Empagliflozin | 164 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 145 | 39 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 142 | 40 |
| Carvedilol | Carvedilol | 140 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 40 |
| Mounjaro | Tirzepatide | 135 | 21 |
| Furosemide | Furosemide | 131 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 125 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 33 |
| Sertraline Hcl | Sertraline Hcl | 109 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 108 | 33 |
| Farxiga | Dapagliflozin Propanediol | 102 | 29 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 99 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 85 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 84 | 19 |
| Pregabalin | Pregabalin | 82 | 12 |
| Tramadol Hcl | Tramadol Hcl | 82 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 16 |
| Montelukast Sodium | Montelukast Sodium | 81 | 22 |
| Celecoxib | Celecoxib | 79 | 21 |
| Metformin Hcl Er | Metformin Hcl | 79 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 77 | 22 |
| Famotidine | Famotidine | 76 | 20 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 17 |
| Simvastatin | Simvastatin | 70 | 19 |
| Eliquis | Apixaban | 68 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 68 | 16 |
| Lorazepam | Lorazepam | 66 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 61 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 21 |
| Irbesartan | Irbesartan | 59 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 14 |
| Allopurinol | Allopurinol | 56 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 55 | 12 |
| Januvia | Sitagliptin Phosphate | 55 | 18 |
| Sucralfate | Sucralfate | 55 | suppressed |
| Novolog Flexpen | Insulin Aspart | 54 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 11 |
| Synthroid | Levothyroxine Sodium | 52 | 13 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 51 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 48 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Ranolazine Er | Ranolazine | 47 | suppressed |
| Fenofibrate | Fenofibrate | 43 | 12 |
| Ibuprofen | Ibuprofen | 43 | 13 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 41 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 41 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | suppressed |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 13 |
| Trazodone Hcl | Trazodone Hcl | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Meloxicam | Meloxicam | 38 | 11 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Naproxen | Naproxen | 36 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 34 | suppressed |
| Finasteride | Finasteride | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | 12 |
| Methylprednisolone | Methylprednisolone | 32 | 28 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Cephalexin | Cephalexin | 31 | 19 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 20 |
| Tradjenta | Linagliptin | 30 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 18 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 18 | suppressed |
| Telmisartan | Telmisartan | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | 14 |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Nifedipine Er | Nifedipine | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Repaglinide | Repaglinide | 14 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 14 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Serevent Diskus | Salmeterol Xinafoate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Kerendia | Finerenone | 12 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Victoza 3-Pak | Liraglutide | 12 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $126.99 · 2 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, LYMPHA PRESS OPTIMAL PLUS(US) BT, PCD-51 731A (US) - White, PCD-52 737A (US) White | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error